Potent alfa galactosyl ceramide analogues targeting invariant natural killer T-cells (iNKT) for selective boosting of cellular immunity. Best-in-class when benchmarked to other Th1-skewing Galcer analogues (IL-12/IFNg/IL-4 profiles). Less IL-4 production compared to aGalCer. No acute toxicity. Druggable profile and optimized for easy synthesis. Proof of concept Enhanced primary and boosted CD8+ Tcell responses in immunised mice.
Novel class of superior Th1 polarizing glycolipids valuable as vaccine adjuvant or adjuvant therapy in oncology.
+32 495 707 334